-- Six abstracts accepted for presentation at
-- Increased enrollment target for HGB-206 study of LentiGlobin® in severe sickle cell disease (SCD) from eight patients to 20 patients –-
-- Published a paper on megaTAL genome editing platform in Science
Translational Medicine with collaborators at Seattle Children’s
-- Ended quarter with
-- Company will discuss ASH abstract data and business updates in a
conference call tomorrow at
“2015 continues to be a year of significant advancement for our programs
in beta-thalassemia, sickle cell disease and oncology, which is
reflected in our strong presence at ASH this year. We are excited about
the progress we’ve made in the third quarter in enrolling the HGB-206
study in severe sickle cell disease, and we have made the decision to
increase the enrollment target in order to gather more data and provide
additional regulatory options,” said
- DATA FROM HGB-204, HGB-205 AND HGB-206 CLINICAL STUDIES OF LENTIGLOBIN TO BE PRESENTED AT ASH – Updated data from the HGB-204 study of LentiGlobin in beta-thalassemia major and the HGB-205 study in beta-thalassemia major and severe sickle cell disease (SCD) will be highlighted in separate oral presentations at the ASH annual meeting in December. Initial early data from the HGB-206 study of LentiGlobin in severe SCD will be presented in a poster.
- DATA FROM PRE-CLINICAL STUDIES OF BB2121 TO BE PRESENTED AT ASH -- bluebird bio will also present data from its lead oncology program, bb2121 at ASH – the first bluebird bio oncology data to be presented at a major medical meeting. Three poster presentations will highlight preclinical data and manufacturing improvements made to the anti-BCMA CAR-T program.
- INCREASED ENROLLMENT TARGET FOR HGB-206 STUDY IN SEVERE SCD – Announced plan to increase enrollment in the U.S.-based HGB-206 study in severe SCD from eight patients to 20 patients to gain additional data and experience with LentiGlobin in SCD. bluebird bio plans to provide an update on enrollment in all three LentiGlobin clinical studies at the ASH meeting in December.
PUBLISHED GENOME EDITING PAPER IN SCIENCE TRANSLATIONAL MEDICINE –
Along with collaborators at the
Center for Immunity and Immunotherapyat Seattle Children’s Research Institute, published “Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template” in Science Translational Medicine. The findings showed that it is possible to edit the CCR5 gene to enable T cells to both resist and kill HIV. They also showed that the megaTAL nuclease platform allows researchers to place edited genes very precisely in the genome, leading to precise location and control of expression of the edited gene.
Third Quarter 2015 Financial Results and Financial Guidance
Cash Position: Cash, cash equivalents and marketable securities
September 30, 2015were $901.7 million, compared to $492.0 millionas of December 31, 2014, an increase of $409.7 million, which was primarily driven by the June 2015equity financing.
Revenues: Collaboration revenue was
$1.3 millionfor the third quarter of 2015 compared to $6.3 millionfor the third quarter of 2014. The decrease is a result of an amendment to our collaboration agreement with Celgenein the second quarter of 2015.
R&D Expenses: Research and development expenses were
$30.4 millionfor the third quarter of 2015, compared to $16.6 millionfor the same period in 2014, an increase of $13.8 million. The increase in research and development expenses was primarily attributable to a $6.6 millionincrease in employee compensation and benefit expense to support our overall growth and a $3.6 millionincrease in expenses necessary to support the advancement of our clinical and pre-clinical programs.
G&A Expenses: General and administrative expenses were
$13.7 millionfor the third quarter of 2015, compared to $6.6 millionfor the same period in 2014, an increase of $7.1 million. The increase in general and administrative expenses was primarily attributable to a $5.7 millionincrease in employee compensation and benefit expense to support our overall growth.
Net Loss: Net loss was
$42.9 millionfor the third quarter of 2015, compared to net loss of $17.0 millionfor the third quarter of 2014.
Financial guidance: bluebird bio expects that its cash, cash
equivalents and marketable securities of
$901.7 millionas of September 30, 2015will be sufficient to fund its current operations through 2018.
Investor Conference Call and Webcast Information
bluebird bio will host a conference call and webcast at
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of beta-thalassemia major; a single-center Phase 1/2 study in
bluebird bio has operations in
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s financial condition and results of operations, the sufficiency of its cash, cash equivalents and marketable securities, as well as the advancement of, and anticipated development and regulatory milestones and plans related to the Company’s product candidates and clinical studies. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of cessation or delay of any of the ongoing or planned clinical studies or development activities for our product candidates, the risk of a delay in the enrollment of patients in the Company’s clinical studies, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that our collaborations will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent annual report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the
Availability of other information about bluebird bio
Investors and others should note that we communicate with our investors and the public using our company website (www.bluebirdbio.com), our investor relations website (http://www.bluebirdbio.com/investor-splash.html), including but not limited to investor presentations and FAQs,
|bluebird bio, Inc.|
|Consolidated Statements of Operations Data|
|(in thousands, except per share data)|
Three months ended
Nine months ended
|Research and license fees||—||115||—||285|
|Research and development||30,395||16,649||98,380||42,043|
|General and administrative||13,704||6,648||31,765||17,924|
Change in fair value of contingent
|Total operating expenses||44,451||23,375||132,685||60,045|
|Loss from operations||(43,127||)||(17,010||)||(120,078||)||(41,010||)|
|Other income (expense), net||263||(20||)||630||48|
|Loss before income taxes||(42,864||)||(17,030||)||(119,448||)||(40,962||)|
|Income tax (expense) benefit||(60||)||-||(60||)||11,797|
|Net loss per share - basic and diluted:||$||(1.18||)||$||(0.61||)||$||(3.52||)||$||(1.14||)|
|Weighted-average number of common shares used in computing net loss per share - basic and diluted:||36,384||28,115||33,979||25,593|
|bluebird bio, Inc.|
|Consolidated Balance Sheets Data|
|September 30,||December 31,|
|Cash, cash equivalents and marketable securities||$||901,711||$||492,003|
|Total stockholders' equity||889,006||491,257|
Source: bluebird bio, Inc.
Investors and Media:
bluebird bio, Inc.
Manisha Pai, 617-245-2107
Pure Communications, Inc.
Dan Budwick, 973-271-6085